Ivabradine · Corlanor

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Heart Failure

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

Also approved (1)
CA
  • LANCORA® (ivabradine tablets) is indicated for: • the treatment of stable chronic heart failure with reduced left ventricular ejection fraction (≤ 35%) in adult patients with NYHA Classes II or III who are in sinus rhythm with a resting heart rate ≥ 77 beats per minute, to reduce the incidence of cardiovascular mortality and hospitalisations for worsening heart failure. LANCORA® should be administered in combination with standard chronic heart failure therapies (see 14 CLINICAL TRIALS). LANCORA® should be initiated and up-titrated under the supervision of a physician who is experienced...
Product first approved 2016Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (19)
Heart Failure
NCT05594342 · The Young Investigator Group of Cardiovascular Research
2022-07-01 – 2023-01-01 · Heart Failure, Cardiogenic Shock, Ischemic Heart Disease
What this study did
NCT04308031 · Chun-Yao Huang
2018-08-26 – 2020-12-31 · Atrial Fibrillation, Ivabradine, Heart Failure
What this study did
NCT01178528 · IRCCS San Raffaele
2009-09 – 2010-10 · Heart Failure
What this study did
Other / comorbidity
NCT07714746 · National Institute of Cardiovascular Diseases, Pakistan
2026-04-20 – 2027-05-31 · Cardiogenic Shock Post Myocardial Infarction
What this study did
NCT05279651 · Jagiellonian University
2022-06-13 – 2026-06-30 · Myocardial Injury After Noncardiac Surgery (MINS), Myocardial Ischemia
What this study did
NCT04031573 · Assistance Publique - Hôpitaux de Paris
2021-02-26 – 2026-04-14 · Septic Shock
What this study did
NCT03718273 · Adolfo Fontenla
2018-10-19 – 2022-06-30 · Atrial Fibrillation, Heart Diseases
What this study did
NCT03105219 · Nanjing First Hospital, Nanjing Medical University
2017-07-01 – 2021-05-30 · Diabetic Kidney Disease
What this study did
NCT04030546 · Vilnius University
2019-06-01 – 2020-12-31 · Patients With Cancer
What this study did
NCT03182725 · University of California, San Diego
2018-02-06 – 2020-05-08 · Postural Orthostatic Tachycardia Syndrome
What this study did
NCT03619187 · Amgen
2018-11-02 – 2020-02-19 · Heart Transplantation, Elevated Resting Heart Rate
What this study did
NCT02584439 · University Hospital, Rouen
2015-12-03 – 2019-07-15 · Healthy, Vascular Stiffness, Aging
What this study did
NCT03485482 · Ain Shams University
2018-03-01 – 2018-03-23 · Cardiovascular Diseases
What this study did
NCT01657136 · Policlinico Casilino ASL RMB
2013-09 – 2016-09 · Inappropriate Sinus Tachycardia
What this study did
NCT01022463 · Govind Ballabh Pant Hospital
2009-11 – 2010-10 · Mitral Stenosis
What this study did
NCT00143507 · Institut de Recherches Internationales Servier
2004-12 – 2008-02 · Coronary Disease, Ventricular Dysfunction, Left
What this study did
NCT00202566 · Institut de Recherches Internationales Servier
2005-06 – 2007-10 · Angina Pectoris
What this study did
Phase 2/3 (3)
Heart Failure
NCT02188082 · Jiangsu HengRui Medicine Co., Ltd.
2014-05 – 2017-08 · Chronic Systolic Heart Failure
What this study did
Other / comorbidity
NCT07268170 · Gødstrup Hospital
2025-12-15 – 2028-09-30 · Coronary Arterial Disease (CAD), Ischemic Heart Disease (IHD)
What this study did
NCT04285736 · Cairo University
2014-12 – 2016-05 · NSTEMI
What this study did
Phase 2 (14)
Heart Failure
NCT04405804 · Bambino Gesù Hospital and Research Institute
2020-06-20 – 2021-05 · Acute Heart Failure, Dilated Cardiomyopathy
What this study did
NCT00757055 · St Vincent's University Hospital, Ireland
2012-12 – 2014-01 · Diastolic Heart Failure
What this study did
NCT00202579 · Institut de Recherches Internationales Servier
2004-09 – 2006-02 · Heart Failure, Congestive
What this study did
Other / comorbidity
NCT07881302 · Kathryn Armstrong
2026-11 – 2028-05 · Dysautonomia of Adolescence
What this study did
NCT04186286 · University of Calgary
2021-02-01 – 2026-12-31 · Postural Tachycardia Syndrome
What this study did
NCT06305806 · Kanecia Obie Zimmerman
2024-03-11 – 2025-12-17 · Long COVID, Long Covid19, Long Covid-19
What this study did
NCT06305780 · Kanecia Obie Zimmerman
2024-03-11 – 2025-07-09 · Long COVID, Long Covid19, Long Covid-19
What this study did
NCT05141071 · Cairo University
2021-11-25 – 2022-06-05 · Septic Shock
What this study did
NCT04580342 · Ahmed talaat ahmed aly
2020-10-15 – 2021-01-30 · Hypotension
What this study did
NCT03137537 · Dana-Farber Cancer Institute
2018-02-27 – 2020-11-18 · Lymphoma, Autonomic Imbalance, Cancer Survivorship
What this study did
NCT02623569 · Xintong Pharmacy Company
2014-10 – 2017-06 · Angina Pectoris
What this study did
NCT01761825 · Tel-Aviv Sourasky Medical Center
2012-12 – 2013-02 · Postural Tachycardia Syndrome
What this study did
NCT01186783 · Martin-Luther-Universität Halle-Wittenberg
2010-05 – 2012-05 · Multiple Organ Dysfunction Syndrome
What this study did
NCT00865917 · Hannover Medical School
2008-11 – 2010-12 · Postural Orthostatic Tachycardia Syndrome
What this study did
Phase 1/2 (1)
Heart Failure
NCT02236247 · University of Sao Paulo
2013-05 – 2017-08 · Decompensated Heart Failure
What this study did
Phase 1 (3)
Other / comorbidity
NCT07717710 · University of British Columbia
2026-10-01 – 2026-12 · Healthy Adult
What this study did
NCT03987204 · Yale University
2019-06-15 – 2019-09-17 · Atrial Fibrillation, Atrial Fibrillation, Persistent
What this study did
NCT01804010 · Asan Medical Center
2007-05 – 2007-11 · Healthy Individual
What this study did
Phase 4 (33)
Heart Failure
NCT01868880 · Policlinico Casilino ASL RMB
2016-02 – 2023-12 · Heart Rate Control in ICD Patients With Heart Failure
What this study did
NCT02973594 · University of Colorado, Denver
2016-11 – 2023-06-30 · Dilated Cardiomyopathies, Idiopathic, Heart Failure, Systolic, Ventricular Remodeling, Electrical Remodeling
What this study did
NCT03168529 · Phillip Levy
2018-07-01 – 2021-12-31 · Heart Failure
What this study did
NCT03631654 · University of Maryland, Baltimore
2020-10-01 – 2021-08-31 · Heart Failure NYHA Class IV
What this study did
NCT04448899 · Damanhour University
2020-06-01 – 2021-02-05 · Congestive Heart Failure
What this study did
NCT03387605 · Loyola University
2018-03-15 – 2020-06 · Heart Failure, Cardiogenic Shock, Tachycardia
What this study did
NCT03456856 · Amgen
2017-09-28 – 2019-05-20 · Heart Failure (HF)
What this study did
NCT02827500 · Duke University
2016-07 – 2018-10-15 · Heart Failure
What this study did
NCT02166060 · Medical University of Warsaw
2014-08 – 2016-10 · Heart Failure
What this study did
NCT02046044 · Kocaeli University
2014-01 – 2014-10 · Heart Failure
What this study did
NCT01699776 · Cocco, Giuseppe, M.D.
2008-04 – 2012-02 · Cardiac Failure
What this study did
NCT01373619 · University of Campania Luigi Vanvitelli
2010-01 – 2012-01 · Heart Failure
What this study did
Other / comorbidity
NCT07135258 · The University of Hong Kong
2025-10-01 – 2027-10-01 · Atrial Fibrillation (Permanent), Atrial Fibrillation (AF)
What this study did
NCT05882708 · Second Affiliated Hospital of Guangzhou Medical University
2023-06-01 – 2027-05-31 · Sepsis, Ivabradine, Hemodynamics, Heart Rate Control
What this study did
NCT05481177 · Uniformed Services University of the Health Sciences
2023-06-14 – 2024-09-01 · Long Haul COVID, Postural Orthostatic Tachycardia Syndrome
What this study did
NCT06371222 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2023-02-01 – 2024-02-01 · Mitral Stenosis
What this study did
NCT05348057 · Qian geng
2021-08-01 – 2022-09-01 · Cardiovascular Diseases
What this study did
NCT05261464 · Mahidol University
2021-01-30 – 2022-06-30 · Heart Rate, Coronary Computed Tomography Angiography
What this study did
NCT04436016 · University Hospital, Geneva
2020-10-05 – 2022-01-11 · Myocardial Injury, Myocardial Ischemia
What this study did
NCT03405831 · Finn Gustafsson
2018-04-17 – 2019-12 · Cardiac Allograft Vasculopathy, Transplanted Heart Complication
What this study did
NCT03437369 · Hospital Universitario Ramon y Cajal
2018-05 – 2019-10 · Cardiogenic Shock
What this study did
NCT03866395 · Azienda Policlinico Umberto I
2015-03-05 – 2017-03-07 · Angina Pectoris, Stable
What this study did
NCT03245996 · Tartu University Hospital
2015-06 – 2016-09 · Aortic Blood Pressure
What this study did
NCT02507050 · Liverpool Heart and Chest Hospital NHS Foundation Trust
2016-03 – 2016-03 · Coronary Artery Disease, Angina
What this study did
NCT01755663 · Col. Suthee Panichkul
2014-12 – 2015-12 · Coronary Artery Disease
What this study did
NCT02681978 · Campus Bio-Medico University
2014-02 – 2015-07 · Coronary Artery Disease
What this study did
NCT01768585 · University Hospital, Saarland
2012-12 – 2014-12 · Coronary Artery Disease, Coronary Arteriosclerosis
What this study did
NCT01425164 · University of Campania Luigi Vanvitelli
2011-01 – 2012-06 · Coronary Heart Disease, Angina, Hemodialysis
What this study did
NCT01029223 · Bayside Health
2008-10 – 2011-12 · Blood Pressure
What this study did
NCT00825123 · Bayside Health
2008-10 – 2011-11-08 · Central Arterial Pressure
What this study did
NCT00815100 · Hospital Universitario de Canarias
2009-04 – 2011-09-07 · Acute Coronary Syndromes
What this study did
NCT01365286 · Medical University of Lodz
2009-05 – 2011-01 · Asthma, Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01364077 · University of Campania Luigi Vanvitelli
2010-01 – 2011-01 · High Heart Rate
What this study did
Early phase / not applicable (15)
Heart Failure
NCT03650205 · University of Sao Paulo
2019-01-22 – 2021-12-01 · Neoplasms, Heart Failure, Cardiotoxicity, Chemotherapy Effect, Oncology
What this study did
NCT03701880 · Ain Shams University
2018-09-16 – 2019-12-23 · Heart Failure With Reduced Ejection Fraction, Decompensated Heart Failure
What this study did
NCT03830957 · Rajaie Cardiovascular Medical and Research Center
2018-11-26 – 2019-12 · Heart Failure, CT Angiography, Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Systolic, Heart Failure,Congestive, Heart Failure, Diastolic, Heart Rate Low
What this study did
NCT02086422 · The Leeds Teaching Hospitals NHS Trust
2013-07 – 2015-07 · Chronic Heart Failure
What this study did
NCT02354573 · University of Oxford
2011-12 – 2014-01 · Heart Failure
What this study did
Other / comorbidity
NCT07797946 · Minia University
2026-08-01 – 2027-02-01 · Hemodynamic Instability
What this study did
NCT04111133 · Post Graduate Institute of Medical Education and Research, Chandigarh
2020-01-01 – 2026-12-31 · Cirrhotic Cardiomyopathy, Left Ventricular Dysfunction, Cirrhosis, Liver, Portal Hypertension
What this study did
NCT04853797 · Danish Headache Center
2021-05-11 – 2025-07-06 · Headache, Migraine Without Aura
What this study did
NCT06505668 · All India Institute of Medical Sciences, Bhubaneswar
2023-08-01 – 2025-06-30 · Treatment Resistant Schizophrenia, Clozapine Adverse Reaction, Heart Rate Variability, Tachycardia
What this study did
NCT06742164 · Ain Shams University
2024-12-30 – 2025-06-30 · Heart Rhythm Disorder
What this study did
NCT06670690 · Menoufia University
2023-09-01 – 2023-10-01 · Intraoperative Bleeding
What this study did
NCT03367026 · Peking Union Medical College Hospital
2018-01-01 – 2021-06-30 · Sepsis, Severe
What this study did
NCT04208594 · Alexandria University
2019-12-11 – 2020-05 · Ivabradine, Propranolol, Hypotensive Anesthesia
What this study did
NCT02294292 · Institute of Liver and Biliary Sciences, India
2014-07-01 – 2016-08-31 · Diastolic Dysfunction, Chronic Liver Disease
What this study did
NCT01039389 · Insel Gruppe AG, University Hospital Bern
2009-10 – 2013-03 · Coronary Artery Disease
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Early phase / not applicable (1)
Heart Failure
NCT02247245 · University of Leeds
2014-09 – 2015-09 · Chronic Heart Failure, Atrial Fibrillation, Arrhythmia, Sinus
What this study did

Competitive landscape

This drug's own stage for Heart Failure: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ivabradine (Corlanor): this drugApprovedSmall moleculeIf (funny) channelReliable signal
NCT02441218: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. (All over the study (up to 42 months).): Ivabradine 793 participants | Placebo 937 participants
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT04564742: Primary hierarchical composite outcome (win ratio analysis, DAPA-MI): win ratio 1.34 (95% CI 1.20-1.50), P<0.001, favoring dapagliflozin over placebo; n=4017 (2019 dapagliflozin vs 1998 placebo)
NCT03619213: Primary composite outcome (worsening heart failure or cardiovascular death): dapagliflozin 16.4% vs placebo 19.5%; hazard ratio 0.82 (95% CI 0.73-0.92, p<0.001)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03057951: Primary composite endpoint (CV death or HF hospitalization) event rate: 13.8% (empagliflozin) vs 17.1% (placebo); HR 0.79, 95% CI 0.69-0.90; 21% relative risk reduction.
NCT03057977: Primary composite outcome (cardiovascular death or hospitalization for worsening heart failure) at median 16 months: 19.4% (361/1863) with empagliflozin vs 24.7% (462/1867) with placebo; hazard ratio 0.75 (95% CI 0.65-0.86), P<0.001
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT03037931: Primary endpoint, hierarchical composite of death and heart failure hospitalization at 12 months and change in 6-minute walk distance at 6 months (significance level 0.01): unmatched win ratio 1.10 (99% CI 0.99 to 1.23), Wilcoxon-Mann-Whitney P=0.02. Components, ferric carboxymaltose vs placebo: deaths 131 (8.6%) vs 158 (10.3%); heart failure hospitalizations 297 vs 332; 6-minute walk change +8 vs +4 m. missed
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT04435626: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Finerenone (BAY94-8862) 1083 events | Placebo 1283 events
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2Weak signalFeatured results are non-efficacy only in this race
Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Isosorbide Dinitrate / Hydralazine (BiDil)ApprovedSmall moleculeHydralazine/isosorbide dinitrate (fixed combination)Partial signal
NCT00047775: Primary composite score (all-cause mortality, first heart-failure hospitalization, quality of life) favoured isosorbide dinitrate/hydralazine vs placebo (p=0.021); the trial stopped early for a 43% reduction in all-cause mortality (p=0.012) (BiDil label, A-HeFT).
Sacubitril / Valsartan (Entresto)ApprovedSmall moleculeNeprilysin + Angiotensin II receptor (dual)Partial signal
NCT01035255: Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization (up to 51 months): LCZ696 — Primary Composite: 914 participants; CV death: 558 participants; 1st HF Hospitalization: 537 participants | Enalapril — Primary Composite: 1117 participants; CV death: 693 participants; 1st HF Hospitalization: 658 participants
NCT01920711: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. (Total follow up time (up to 57 months)): LCZ696 — Primary Composite Events: 894 Events; Total Hospitalizations for heart failure: 690 Events; Cardiovascular death: 204 Events | Valsartan — Primary Composite Events: 1009 Events; Total Hospitalizations for heart failure: 797 Events; Cardiovascular death: 212 Events missed
Sotagliflozin (Inpefa)ApprovedSmall moleculeSGLT1/2 (dual)Partial signal
NCT03315143: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 30 months): Sotagliflozin 5.6 events per 100-person years | Placebo 7.5 events per 100-person years
NCT03521934: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 21.9 months): Sotagliflozin 51 events per 100-person years | Placebo 76.3 events per 100-person years
Torsemide (Soaanz)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Vericiguat (Verquvo)ApprovedSmall moleculeSoluble guanylate cyclasePartial signal
NCT02861534: CV death or first HF hospitalization, vericiguat vs placebo: 897 of 2526 (35.5%) vs 972 of 2524 (38.5%) over a median 10.8 months; HR 0.90 (95% CI 0.82 to 0.98), P = 0.02. Met.
NCT05093933: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years (Up to approximately 36 months (from randomization to the primary completion data cutoff)): Vericiguat 11.3 Pts. with event/100 patient-yrs at risk | Placebo 12.2 Pts. with event/100 patient-yrs at risk missed
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet gradedNo reviewed efficacy summary in this indication
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
CardiAMPPhase 3Cell therapyCardiac cell therapyPartial signal
NCT02438306: 3-tiered Finkelstein-Schoenfeld primary endpoint at 12 months (interim, 102 of eventual 125 patients): Tier 1 all-cause death 5.6% CardiAMP vs 5.3% control (P=.42); Tier 2 MACCE 16.7% vs 15.8% (P=.82); Tier 3 6MWT change +36.1m vs +33.4m (P=.6) - none reached significance; DSMB futility review concluded the trial was unlikely to meet its primary endpoint missed
CoramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Ferric Derisomaltose (Monoferric / Monofer)Phase 3Iron Complex (iv)Iron repletionWeak signal
NCT00537186: Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks.
HiCM-188 (allogeneic iPSC-Cardiomyocytes)Phase 3Cell therapyCardiac cell therapyPartial signalNo reviewed efficacy summary in this indication
Icodextrin (peritoneal Ultrafiltration) (Extraneal)Phase 3Glucose Polymer Solution (peritoneal Dialysis)Peritoneal ultrafiltrationWeak signal
NCT00368641: All-cause Hospitalization (Unadjusted) (6 to 24 months): Intervention Group 5.33 hospitalizations per year (95% CI 3.13 to 9.05) vs Standard Therapy 1.69 hospitalizations per year (95% CI 0.95 to 2.99)
Levosimendan (Simdax)Phase 3Small moleculeCardiac troponin C (calcium sensitizer)Partial signal
NCT00348504: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P = .40). missed
NCT00048425: REVIVE II, n=600: 5-day clinical-course composite primary endpoint improved 33% more often and worsened 26% less often with levosimendan vs placebo (p=0.015).
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
Omecamtiv MecarbilPhase 3Small moleculeCardiac myosin (activator)Reliable signal
NCT02929329: Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Omecamtiv Mecarbil 37% vs Placebo 39.1%
NCT03759392: Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 (Baseline and Week 20): Omecamtiv Mecarbil -0.239 mL/min/kg (Standard Error 0.1718) vs Placebo 0.207 mL/min/kg (Standard Error 0.2412) missed
OPC-61815 (Samtasu)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT03772041: Change From Baseline in Body Weight (Baseline, Day 6): OPC-61815 Injection 16 mg -1.67 kg (95% CI -1.93 to -1.41) vs Tolvaptan Tablet 15mg -1.36 kg (95% CI -1.62 to -1.1)
QiShenYiQiPhase 3BotanicalTraditional Chinese medicine (multi-component)Partial signalNo reviewed efficacy summary in this indication
Recombinant Human Neuregulin-1 (rhNRG-1) (Neucardin)Phase 3Protein / enzyme therapeuticErbB2/ErbB4 (neuregulin pathway)Partial signalNo reviewed efficacy summary in this indication
Rexlemestrocel-LPhase 3Cell therapyMesenchymal precursor cells (MPCs)Weak signalFeatured results are safety only in this race
Sotatercept (Winrevair)Phase 3Protein / enzyme therapeuticActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Samsca)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT00071331: All-cause mortality: tolvaptan 25.9% vs placebo 26.3% (HR 0.98, 95% CI 0.87-1.11, P=.68). Composite of CV death or HF hospitalization: tolvaptan 42.0% vs placebo 40.2% (HR 1.04, 95% CI 0.95-1.14, P=.55). missed
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
DanicamtivPhase 2/3Small moleculeCardiac myosin (activator)Weak signal
NCT03447990: Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts.
IstaroximePhase 2/3Small moleculeNa-K ATPase / SERCA2aPartial signal
NCT02617446: Change in E/Ea Ratio (24 hours): Istaroxime 0.5 µg/kg/Min -4.55 Unitless ratio (95% CI -6.05--3.04) vs Placebo Cohort I -1.55 Unitless ratio (95% CI -3.77-0.67) vs Istaroxime 1.0 µg/kg/Min -3.16 Unitless ratio (95% CI -4.09--2.24) vs Placebo Cohort II -1.08 Unitless ratio (95% CI -2.30-0.13); p=0.029 (Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I), p=0.009 (Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II)
AC01Phase 2Small moleculeGhrelin receptorWeak signalNo reviewed efficacy summary in this indication
ADR-002KPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
Bucindolol (Gencaro)Phase 2Small moleculeBeta-1/beta-2 adrenergic receptor (genotype-guided)Partial signal
NCT01970501: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24]. (end of treatment week 24): Bucindolol Hydrochloride 35.9 days (IQR 9 to 53) vs Metoprolol Succinate 33.2 days (IQR 6 to 47) missed
CDR132LPhase 2RNA / oligonucleotidemicroRNA-132Weak signalFeatured results are safety only in this race
Corteria COR-1167Phase 2PeptideCorticotropin-releasing factor receptor 2not yet gradedNo reviewed efficacy summary in this indication
DelocamtenPhase 2Small moleculeCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
DeramiocelPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HRS-9057Phase 2Small moleculeVasopressin V1a/V2 receptor (dual)Weak signalNo reviewed efficacy summary in this indication
HU6Phase 2Small moleculeMitochondrial uncouplingPartial signal
NCT05284617: Weight change at 3 months (450 mg HU6 dose): -6.8 lb from baseline (p<0.0001); -6.3 lb vs placebo (p=0.003)
Jia Shen TabletPhase 2BotanicalMulti-target (ginsenoside)Weak signalNo reviewed efficacy summary in this indication
JK07Phase 2Biologic (subtype unspecified)HER3 × ErbB4Weak signalFeatured results are safety only in this race
JTT-861Phase 2Small moleculePyruvate dehydrogenasePartial signalNo reviewed efficacy summary in this indication
Mavacamten (Camzyos)Phase 2Small moleculeCardiac myosin (inhibitor)Weak signalFeatured results are safety only in this race
Ninerafaxstat (IMB-101)Phase 2Small moleculeCardiac fatty-acid oxidationWeak signal
NCT04826159: Primary, resting cardiac PCr/ATP change from baseline (single arm, no comparator): Part 1 (type 2 diabetes and obesity) +0.39 (95% CI 0.16 to 0.62; P=0.002); Part 2 (with HFpEF) +0.15 (95% CI 0.03 to 0.26; P=0.02). Dobutamine-stress PCr/ATP (Part 1) is not reported in the abstract.
PexerelgonPhase 2Small moleculeRelaxin receptor (RXFP1) / relaxinPartial signalNo reviewed efficacy summary in this indication
PF-07328948Phase 2Small moleculeBranched-chain ketoacid dehydrogenase kinase (BDK)not yet gradedNo reviewed efficacy summary in this indication
R2R01Phase 2PeptideRelaxin receptor (RXFP1) / relaxinWeak signalNo reviewed efficacy summary in this indication
RibupatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Safiglipron (HRS-7535)Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
TovinontrinePhase 2Small moleculePDE9Partial signalNo reviewed efficacy summary in this indication
Umiposgene Parvec (AB-1002)Phase 2Gene therapy / editingProtein inhibitor-1 (gene therapy)Weak signal
NCT04179643: Phase 1 first-in-human trial of a single antegrade coronary infusion of AB-1002 in NYHA III non-ischemic heart failure: no adverse events or serious adverse events were attributed by the investigators to the study treatment. Mean left ventricular ejection fraction rose from 30.5% at baseline to 42.2% at 12 months in cohort 1 and from 24.5% to 36.7% in cohort 2, and all patients with baseline and 12-month assessments had an improvement in ejection fraction of at least 5%.
XTR003Phase 2Diagnostic (pet Tracer)Myocardial fatty-acid metabolism (PET imaging)not yet gradedNo reviewed efficacy summary in this indication
AAV1.SERCA2aPhase 1/2Gene therapy / editingSERCA2a (gene therapy)not yet gradedNo reviewed efficacy summary in this indication
HS-001Phase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
HucMSC Intramyocardial TherapyPhase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
PolyCorePhase 1/2SolutionPeritoneal ultrafiltrationnot yet gradedNo reviewed efficacy summary in this indication
Anhui HygeianCells EE001Phase 1Biologic (subtype unspecified)Cardiac cell therapyWeak signalNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 14 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Corlanor (Ivabradine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1Healthy AdultRecruiting
Est. primary completion 2026-12 · NCT07717710 · CT.gov ↗
What to watch
Phase 4Sepsis, Ivabradine, Hemodynamics, Heart Rate ControlRecruiting
Est. primary completion 2026-12-31 · NCT05882708 · CT.gov ↗
What to watch
2027 (3)
February 2027 (1)
Early phase / not applicableHemodynamic InstabilityNot yet recruiting
Est. primary completion 2027-02-01 · NCT07797946 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Cardiogenic Shock Post Myocardial InfarctionRecruiting
Est. primary completion 2027-05-31 · NCT07714746 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4Atrial Fibrillation (Permanent), Atrial Fibrillation (AF)Not yet recruiting
Est. primary completion 2027-10-01 · NCT07135258 · CT.gov ↗
What to watch
2028 (2)
May 2028 (1)
Phase 2Dysautonomia of AdolescenceNot yet recruiting
Est. primary completion 2028-05 · NCT07881302 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2/3Coronary Arterial Disease (CAD), Ischemic Heart Disease (IHD)Enrolling by invitation
Est. primary completion 2028-09-01 · NCT07268170 · CT.gov ↗
What to watch

See the full readout calendar ↗